Treatment and Control of BP and Lipids in Patients with Hypertension and Additional Risk Factors
- PDF / 135,193 Bytes
- 9 Pages / 592.44 x 751.18 pts Page_size
- 62 Downloads / 190 Views
ORIGINAL RESEARCH ARTICLE
© 2007 Adis Data Information BV. All rights reserved.
Treatment and Control of BP and Lipids in Patients with Hypertension and Additional Risk Factors Verna Welch1 and Simon S.K. Tang2 1 2
Morehouse School of Medicine, Atlanta, Georgia, USA Pfizer Global Pharmaceuticals, New York, New York, USA
Abstract
Background: NCEP ATP III (National Cholesterol Education Program Adult Treatment Panel III) guidelines recommend that for patients at high risk for cardiovascular disease (CVD), lipid-lowering therapy should be considered even at relatively low cholesterol levels (low-density lipoprotein-cholesterol ↓100 mg/dL). Furthermore, the ASCOT-LLA (Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm) has demonstrated the importance of statin therapy in the primary prevention of major cardiovascular events in people with hypertension and ↓3 cardiovascular risk factors with total cholesterol levels of ↑250 mg/dL (↑6.5 mmol/L). Objective: To analyze the utilization of antihypertensive and lipid-lowering medications, and associated rates of BP and cholesterol goal attainment, in the primary prevention of CVD among patients with hypertension. Study design: Retrospective cross-sectional analysis of data from outpatient medical records (including BP, comorbidities, and medications) abstracted for visits between 1 October 2001 and 30 September 2003 to the Atlanta Veterans Affairs Medical Center (VAMC). Patients were tracked for at least 1 year. Patients: Veterans newly diagnosed with hypertension, with lipid levels ↑240 mg/dL (↑6.2 mmol/L) and no prior coronary heart disease, and who were seeking care at the VAMC were included in the analysis. Patients were grouped by the presence of
Data Loading...
